0 CHECKOUT

Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015

  • ID: 3293088
  • May 2015
  • 96 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Arsanis Biosciences GmbH
  • Melinta Therapeutics, Inc
  • Northern Antibiotics Oy
  • Novan, Inc.
  • Phico Therapeutics Ltd.
  • Soligenix, Inc.
  • MORE

Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015

Summary

This, ‘Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015’, provides an overview of the Klebsiella Pneumoniae Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Arsanis Biosciences GmbH
  • Melinta Therapeutics, Inc
  • Northern Antibiotics Oy
  • Novan, Inc.
  • Phico Therapeutics Ltd.
  • Soligenix, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Klebsiella Pneumoniae Infections Overview
Therapeutics Development
Pipeline Products for Klebsiella Pneumoniae Infections - Overview
Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis
Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies
Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes
Klebsiella Pneumoniae Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Klebsiella Pneumoniae Infections - Products under Development by Companies
Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes
Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development
Arsanis Biosciences GmbH
Cellceutix Corporation
Debiopharm International S.A.
Melinta Therapeutics, Inc
Merck & Co., Inc.
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Pfizer Inc.
Phico Therapeutics Ltd.
Sarepta Therapeutics, Inc.
Shionogi & Co., Ltd.
Soligenix, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
Theraclone Sciences, Inc.
Trana Discovery, Inc.
Klebsiella Pneumoniae Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BXN-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-618 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-1807 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTIX-1278 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debio-1454 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MVX-506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-7061 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-741 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOSO-95300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-4428 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXP-792 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXP-873 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM-295291 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM-369926 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-138 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Klebsiella Pneumoniae Infections - Recent Pipeline Updates
Klebsiella Pneumoniae Infections - Dormant Projects
Klebsiella Pneumoniae Infections - Discontinued Products
Klebsiella Pneumoniae Infections - Product Development Milestones
Featured News & Press Releases
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Merck & Co., Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Northern Antibiotics Oy, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Novan, Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Ltd., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H1 2015
Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H1 2015
Klebsiella Pneumoniae Infections - Dormant Projects, H1 2015
Klebsiella Pneumoniae Infections - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Arsanis Biosciences GmbH
Cellceutix Corporation
Debiopharm International S.A.
Melinta Therapeutics, Inc
Merck & Co., Inc.
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Pfizer Inc.
Phico Therapeutics Ltd.
Sarepta Therapeutics, Inc.
Shionogi & Co., Ltd.
Soligenix, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
Theraclone Sciences, Inc.
Trana Discovery, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.